Diamond-Blackfan anemia is a congenital erythroid hypoplasia. Twenty-five percent
of patients have mutations in a gene encoding ribosomal protein S19. Using an RPS19-deficient
mouse model, Debnath et al. demonstrate the feasibility to cure RPS19-deficient Diamond-Blackfan
anemia by means of lentiviral vectors with cellular promoters that possess a reduced
risk of insertional mutagenesis.
In the present study, the scientists assessed the efficacy of a clinically relevant promoter, the human elongation factor 1α short promoter, with or without the locus control region of the β-globin gene for treatment of RPS19-deficient Diamond-Blackfan anemia. The findings demonstrate that these vectors rescue the proliferation defect and improve erythroid development of transduced RPS19-deficient bone marrow cells.